PAN: Neutropenia (Medicare)

The PAN: Neutropenia (Medicare) program is currently not funded. When available, it offers financial assistance with an annual maximum benefit of $2200 for US and Puerto Rico residents with Medicare/Medicaid who require treatment for neutropenia with drugs like Neulasta, Neupogen, and Granix. The program covers eligible expenses, including off-label drug uses, and eligibility is determined based on need.